Extravazation of therapeutic yttrium-90-ibritumomab tiuxetan (zevalin®): A case report

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 2, 2006, Pages 101-105

  Williams, Gethin ^a   Palmer, Matthew R ^a   Parker, J Anthony ^a   Joyce, Robin ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Adverse drug event; Extravasation; Infusion; Vesicant; Yttrium 90; Yttrium 90 ibritumomab tiuxetan; Zevalin

Indexed keywords

BACITRACIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; BLISTER; CASE REPORT; DRUG EXTRAVASATION; ERYTHEMA; HUMAN; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION EXPOSURE; RADIOIMMUNOTHERAPY;

ANTIBODIES, MONOCLONAL; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; HUMANS; MALE; MIDDLE AGED; RADIATION INJURIES; RADIOIMMUNOTHERAPY; YTTRIUM RADIOISOTOPES;

EID: 33744819754     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.101     Document Type: Article

References (34)

1. National Cancer Institute. Cancer Therapy Evaluation Program, Common Toxicity Criteria, Version 3.0. Online document at: ctep.cancer.gov/reporting/ ctcnew. html Accessed December 30, 2002.
2. Zhu X. Radiation safety considerations with yttrium-90-ibritumomab tiuxetan (Zevalin). Semin Nucl Med 2004;34:20.
3. Hendrix C. Radiation safety guidelines for radioimmunotherapy with yttrium-90-ibritumomab tiuxetan. Clin J Oncol Nurs 2004;8:31.
4. Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol 2004;15:858.
5. Moreno de Vega MJ, Dauden E, Abajo P, et al. Skin necrosis from extravasation of vinorelbine. J Eur Acad Dermatol Venereol 2002;16:488.
6. Kassner E. Evaluation and treatment of chemotherapy extravasation injuries. J Pediatr Oncol Nurs 2000;17: 135.
7. Herrington JD, Figueroa JA. Severe necrosis due to paclitaxel extravasation. Pharmacotherapy 1997;17:163.
8. Weber DA, Eckerman KF, Dillman LT, et al. MIRD: Radionuclide Data and Decay Schemes. New York: The Society of Nuclear Medicine, 1989:159.
9. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from four clinical trials. J Nucl Med 2003;44:465.
10. Gusev IA, Guskova AK, Mettler FA (eds.). Medical Management of Radiation Accidents. New York: CRC Press, 2001:72.
11. Champlin RE, Kastenberg WE, Gale RP. Radiation accidents and nuclear energy: Medical consequences and therapy. Ann Intern Med 1988;109:730.
12. Cersosimo RJ. Monoclonal antibodies in the treatment of cancer, Part 1. Am J Health Syst Pharm 2003;60:1531.
13. Cersosimo RJ. Monoclonal antibodies in the treatment of cancer, Part 2. Am J Health Syst Pharm 2003;60: 1631.
14. Mirick GR, Bradt BM, Denardo SJ, et al. A review of human antiglobulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four-letter words. Q J Nucl Med Mol Imaging 2004;48:251.
15. Borghaei H, Schilder RJ. Safety and efficacy of radioimmunotherapy with yttrium-90-ibritumomab tiuxetan (Zevalin). Semin Nucl Med 2004;34:4.
16. 90Y-ibritumomab tiuxetan (Zevalin). J Exp Ther Oncol 2004;4:305.
17. Chrystal C. Administering continuous vesicant chemotherapy in the ambulatory setting. J Intraven Nurs 1997;20:78.
18. Jordan K, Grothe W, Schmolol HJ. Extravasation of chemotherapeutic agents: Prevention and therapy. Dtsch Med Wochenschr 2005;130:33.
19. D'Andrea F, Onesti MG, Nicoletti GF, et al. Surgical treatment of ulcers caused by extravasation of cytotoxic drugs. Scand J Plast Reconstr Surg Hand Surg 2004;38: 288.
20. Disa JJ, Chang RR, Mucci SJ, et al. Prevention of adriamycin-induced full-thickness skin loss using hyaluronidase infiltration. Plast Reconstr Surg 1998;101: 370.
21. Langstein HN, Duman H, Seelig D, et al. Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg 2002;49:369.
22. Low-Beer BVA. External therapeutic use of radioactive phosphorus I erythema studies. Radiology 1946;47:213.
23. Minsky BD, Siddon RL, Recht A et al. Dosimetry of aqueous 32-P after soft-tissue infiltration following attempted intravenous administration. Health Phys 1987;52:878.
24. Loutfi I, Collier BD, Mohammed AM. Nonosseous abnormalities on bone scans. J Nucl Med Technol 2003;31:149.
25. Shih WJ, Man JK, Coupal J, et al. Axillary lymph node uptake of Tc-99m MIBI resulting from extravasation should not be misinterpreted as metastasis. Ann Nucl Med 1999;13:269.
26. Rose H, Siemsen JK, Extravasation of radioisotopes following vascular catheterization. Radiology 1967;90: 547.
27. Whang SW, Lee SH, Elias PM, et al. Intralesional steroids reduce inflammation from extravasated chemotherapeutic agents. Br J Dermatol 2001;145:680.
28. Albanell J, Baselga S. Systemic therapy emergencies. Semin Oncol 2000;27:347.
29. Tsavaris NB, Komitsopoulou P, Karagiaouris P, et al. Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 1992;30:330.
30. Spugnini EP. Use of hyaluronidase for the treatment of extravasation of chemotherapeutic agents in six dogs. J Am Vet Med Assoc 2002;221:1437.
31. Wang Z, Qiu W, Mendenhall WM. Influence of radiation therapy on reconstructive flaps after radical resection of head and neck cancer. Int J Oral Maxillofac Surg 2003;32:35.
32. Asian G, Terzioglu A, Tuncali D, et al. Consequences of radiation accidents. Ann Plast Surg 2004;52:325.
33. Bui DT, Chunilal A, Mehrara BJ, et al. Outcome of split-thickness skin grafts after external beam radiotherapy. Ann Plast Surg 2004;52:551.
34. Ran X, Yan Y, Cheng T, et al. Effects of combined radiation and thermal burn injury on the survival of skin allograft and immune function in rats. Chin Med J 1998;111:634.